 | | Vol. 10.18 – 11 May, 2022 |
| |
|
|
Adenovirus Type 5 SARS-CoV-2 Vaccines Delivered Orally or Intranasally Reduced Disease Severity and Transmission in a Hamster Model | Investigators demonstrated that hamsters vaccinated by the oral or intranasal route with an adenovirus type 5-vectored SARS-CoV-2 vaccine candidate had robust and cross-reactive antibody responses.
[Science Translational Medicine] |
|
|
|
| | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
Structural Mapping of Antibody Landscapes to Human Betacoronavirus Spike Proteins | Researchers used electron microscopy–based polyclonal epitope mapping to characterize the antibody specificities against β-CoV spike proteins in prepandemic sera or SARS-CoV-2 convalescent sera.
[Science Advances] |
|
|
|
Cumulative SARS-CoV-2 Mutations and Corresponding Changes in Immunity in an Immunocompromised Patient Indicate Viral Evolution within the Host | Scientists reported SARS-CoV-2 immune escape mutations over a period of seven months in an immunocompromised patient with prolonged viral shedding.
[Nature Communications] |
|
|
|
Longitudinal Analyses Reveal Distinct Immune Response Landscapes in Lung and Intestinal Tissues from SARS-CoV-2-Infected Rhesus Macaques | Investigators found that intestinal enterocytes were degraded at three days post-infection but recovered rapidly, revealing that infection had mild effects on the intestine.
[Cell Reports] |
|
|
|
ADAM10 and ADAM17 Promote SARS-CoV-2 Cell Entry and Spike Protein-Mediated Lung Cell Fusion | Scientists identified the host metalloprotease ADAM17 as a facilitator of SARS-CoV-2 cell entry and the metalloprotease ADAM10 as a host factor required for lung cell syncytia formation, a hallmark of COVID-19 pathology.
[EMBO Reports] |
|
|
|
Broad Humoral and Cellular Immunity Elicited by One-Dose mRNA Vaccination 18 Months after SARS-CoV-2 Infection | The authors showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months.
[BMC Medicine] |
|
|
|
Pseudotyped Bat Coronavirus RaTG13 Is Efficiently Neutralised by Convalescent Sera from SARS-CoV-2 Infected Patients | Using RaTG13 and SARS-CoV-2 pseudotypes, investigators compared neutralization using convalescent sera from previously infected patients or vaccinated healthcare workers.
[Communications Biology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
Selective Inhibition of miRNA Processing by a Herpesvirus-Encoded miRNA | Scientists identified viral miRNA-mediated inhibition of host miRNA processing as a cellular mechanism that human herpesvirus 6A exploited to disrupt mitochondrial architecture, evade intrinsic host defences and drive the switch from latent to lytic virus infection.
[Nature] |
|
|
|
Characterization of a Vaccine-Elicited Human Antibody with Sequence Homology to VRC01-Class Antibodies That Binds the C1C2 gp120 Domain | Researchers examined Env-specific B cell receptor sequences from participants in the HVTN 100 clinical trial, a Phase I/II clinical trial of an RV144-like vaccine regimen.
[Science Advances] |
|
|
|
Identification and Characterization of a Novel Enhancer in the HTLV-1 Proviral Genome | Using proviral DNA-capture sequencing, the authors found a previously unidentified viral enhancer in the middle of the human T-cell leukemia virus type 1 (HTLV-1) provirus.
[Nature Communications] |
|
|
|
Reprogramming Dysfunctional CD8+ T Cells to Promote Properties Associated with Natural HIV Control | Scientists showed that targeting the signaling pathways Wnt/TCF-1 and mTORC through GSK3 inhibition to reprogram HIV-specific CD8+ T cells from non-controllers promoted functional capacities associated with natural control of infection.
[Journal of Clinical Investigation] |
|
|
|
IL-25 Blockade Augments Antiviral Immunity during Respiratory Virus Infection | The authors defined a new immune-regulatory role for IL-25 that directly inhibited virus induced airway epithelial cell innate anti-viral immunity.
[Communications Biology] |
|
|
|
The Gut Efflux Pump MRP-1 Exports Oxidized Glutathione as a Danger Signal That Stimulates Behavioral Immunity and Aversive Learning | Investigators showed that multidrug resistance-associated protein-1 (MRP-1) functioned in the basolateral membrane of intestinal cells to transport byproducts of cellular redox reactions to control both molecular and behavioral immunity in Caenorhabditis elegans.
[Communications Biology] |
|
 |
|
|
|
The Clinical Progress of mRNA Vaccines and Immunotherapies | The authors review the clinical progress of mRNA therapy as well as provide an overview and future outlook of the transformative technology behind these mRNA-based drugs.
[Nature Biotechnology] |
|
|
|
Alterations in Microbiota of Patients with COVID-19: Potential Mechanisms and Therapeutic Interventions | Scientists discuss the potential mechanisms by which microbiota-derived metabolites or components modulate the host immune responses to SARS-CoV-2 infection.
[Signal Transduction and Targeted Therapy] |
|
|
|
Dealing with a Mucosal Viral Pandemic: Lessons from COVID-19 Vaccines | Preclinical mucosal vaccines with intranasal or oral administration demonstrate promising results regarding mucosal IgA generation and tissue-resident lymphocyte responses against SARS-CoV-2.
[Mucosal Immunology] |
|
|
|
|
15 Million People Have Died in the Pandemic, WHO Says | Some 15 million people died during the first two years of the COVID-19 pandemic, new figures from the WHO suggest.
[Nature News] |
|
|
|
Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELDâ„¢ IN), a Potent Neutralization Antibody against Omicron BA.2 and All Variants of Concern | Sorrento Therapeutics, Inc. announced that its Phase I study of intranasal STI-9199 has been fully enrolled in healthy volunteers. The study is currently still blinded and ongoing.
[Sorrento Therapeutics, Inc.] |
|
|
|
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases | OPKO Health, Inc. announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases.
[OPKO Health, Inc.] |
|
|
|
|
| June 16 – 17, 2022
Leuven, Belgium |
|
|
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | Ragon Institute of MGH, MIT and Harvard – Cambridge, Massachusetts, United States |
|
|
|
| | The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
| | New York University College of Dentistry – New York, New York, United States |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
